UniQure NV (QURE):企業の財務・戦略的SWOT分析

【英語タイトル】UniQure NV (QURE) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(GDPH389133FSA)・商品コード:GDPH389133FSA
・発行会社(調査会社):GlobalData
・発行日:2021年4月
・ページ数:52
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

UniQure NV (QURE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus (AAV) based gene therapies using its gene technology platform and offers disease-modifying treatments to patients with severe genetic diseases and other devastating diseases. UniQure’s lead product, AMT-060 is a gene therapy for treatment of moderately-severe hemophilia B. It preclinical product include AMT-130, an AAV5 vector for the treatment of Huntington’s disease and AMT-150 for Spinocerebellar Ataxia type 3. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, North Holland, the Netherlands.

UniQure NV Key Recent Developments

Mar 01,2021: uniQure announces 2020 financial results and highlights recent company progress
Dec 02,2020: uniQure to participate in multiple upcoming industry conferences in December
Oct 27,2020: uniQure announces third quarter 2020 financial results and highlights recent company progress
Aug 26,2020: uniQure announces appointment of Ricardo Dolmetsch, Ph.D., as president, research & development
Jul 30,2020: uniQure announces second quarter 2020 financial results and highlights recent company progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
UniQure NV – Key Facts
UniQure NV – Key Employees
UniQure NV – Key Employee Biographies
UniQure NV – Major Products and Services
UniQure NV – History
UniQure NV – Company Statement
UniQure NV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
UniQure NV – Business Description
Other Break-up: Collaboration Revenue
Performance
Other Break-up: License Revenue
Performance
R&D Overview
UniQure NV – Corporate Strategy
UniQure NV – SWOT Analysis
SWOT Analysis – Overview
UniQure NV – Strengths
UniQure NV – Weaknesses
UniQure NV – Opportunities
UniQure NV – Threats
UniQure NV – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
UniQure NV, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 01, 2021: uniQure announces 2020 financial results and highlights recent company progress
Dec 02, 2020: uniQure to participate in multiple upcoming industry conferences in December
Oct 27, 2020: uniQure announces third quarter 2020 financial results and highlights recent company progress
Aug 26, 2020: uniQure announces appointment of Ricardo Dolmetsch, Ph.D., as president, research & development
Jul 30, 2020: uniQure announces second quarter 2020 financial results and highlights recent company progress
Jun 17, 2020: uniQure announces the appointment of Leonard E. Post, Ph.D. to its Board of Directors
Apr 29, 2020: uniQure announces first quarter 2020 financial results and highlights recent company progress
Mar 03, 2020: uniQure to participate in multiple upcoming industry conferences in March
Mar 02, 2020: uniQure announces 2019 financial results and highlights recent company progress
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
UniQure NV, Key Facts
UniQure NV, Key Employees
UniQure NV, Key Employee Biographies
UniQure NV, Major Products and Services
UniQure NV, History
UniQure NV, Subsidiaries
UniQure NV, Key Competitors
UniQure NV, Ratios based on current share price
UniQure NV, Annual Ratios
UniQure NV, Annual Ratios (Cont...1)
UniQure NV, Interim Ratios
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
UniQure NV, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
UniQure NV, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★調査レポート[UniQure NV (QURE):企業の財務・戦略的SWOT分析] (コード:GDPH389133FSA)販売に関する免責事項を必ずご確認ください。
★調査レポート[UniQure NV (QURE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆